Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone designed for improved stability relative to native GHRH in the systems where it was characterised.

In the VaultLabs catalog it sits in the secretagogue research class alongside CJC-1295 and Ipamorelin, but those are different sequences with separate documentation.

Pharmaceutical tesamorelin products under specific indications are finished medicines. VaultLabs supplies laboratory reference material only.

Clinical literature describes metabolic effects of a GHRH-related factor in specific patient populations — pharmaceutical context, not research-powder guidance.

Laboratory uses include receptor-binding assays, method development and comparative secretagogue analytics.

Release is by HPLC with lot-linked certification. Store sealed at 2–8 °C and reconstitute under aseptic laboratory conditions per institutional SOP.

Tesamorelin is not an approved medicine for VaultLabs supply purposes and is not for human use.

Orders are accepted against a research-use declaration. The catalog presentation is a 5 mg lyophilised vial with batch verification when published.

Secretagogue-class peptides are frequently ordered together. Tesamorelin, CJC-1295 and Ipamorelin should appear as distinct line items with distinct lot files even when they ship in the same insulated parcel.

Pharmaceutical tesamorelin products under indication-specific approvals are finished medicines manufactured under pharmaceutical controls. Research-grade lyophilised powder is a different product category with different obligations and no human-use pathway through VaultLabs.

For method development, treat GHRH analogs as moisture-sensitive lyophilised solids: equilibrate vials before opening, minimise open-vial time in humid environments, and record diluent and preparation time for every working solution.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature. Catalog search, invoice lines and LIMS codes should always carry the full compound name and fill strength so Tesamorelin 5mg cannot be confused with CJC-1295 blend SKUs during goods-in. Keep the research-use declaration with the receiving paperwork for institutional audit trails.

GHRH receptor binding assays

Pituitary secretagogue model systems

Comparative GHRH analog analytics

2–8 °C (lyophilized, sealed)

2–8 °C sealed lyophilized storage.

GHRH analogs require sealed cold storage and documented reconstitution under aseptic laboratory conditions.